EUCTR2004-002992-17-Outside-EU/EEA进行中（未招募）不适用
EVOLUTION OF GROWTH RATE IN CHILDREN WITH GROWTH RETARDATION RELATED TO LONG-TERM GLUCOCORTICOSTEROID THERAPY AND TREATED BY GENOTONORM®
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- Pfizer, Inc.
- 入组人数
- 98
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Evidence of a personally signed and dated informed consent document indicating that
- •the subject (or a legal representative) has been informed of all pertinent aspects of the study.
- •Subjects who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
- •Male and female subjects of childbearing potential must agree to use a highly effective method of contraception throughout the study and for 28 days after the last dose of assigned treatment. A subject is of childbearing potential if, in the opinion of the investigator, he/she is biologically capable of having children and is sexually active.
- •Female subjects who are not of childbearing potential (ie, meet at least one of the following criteria):
- •Have undergone hysterectomy or bilateral oophorectomy;
- •Have medically confirmed ovarian failure or
- •Are medically confirmed to be post menopausal (cessation of regular menses for at least 12 consecutive months with no alternative pathological or physiological cause; laboratory confirmation LH and FSH may be indicated if menopause is in doubt.
- •Subjects who are clinically pre pubertal
- •A request for GH treatment may be issued if all the following criteria are fulfilled
- •1. Bone age < 15 years for a boy and <13 years for a girl.
- •2. Naïve child: Measured Height < -2 SD.
- •3. Child currently treated by GH: Annual Growth Rate = 0 SD for CA.
- •4. Glucocorticosteroid treatment over the last 12 months at least.
- •5. Glucocorticosteroid treatment is anticipated to be sustained for 1 more year at least.
- •6. GH treatment request by a physician who can initiate Genotonorm® treatment according to the French SCP. That is to say a physician working in a hospital pediatric department or in a hospital endocrinology and metabolic disease department and, who is a pediatrician and/or a pediatric endocrinologist.
- •7. The child benefits of the French social security cover.
- •8. Evidence of a personally signed and dated informed consent document indicating that the patient's parents/guardians and from the patient himself/herself if he/she is able to receive and understand the information have been informed of all pertinent aspects of the trial.
- •GH treatment approved by the Treatment monitoring committee
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 97
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 1
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Glucose intolerance on an Oral Glucose Tolerance Test dated less than 3 months or
- •diabetes mellitus.
- •2. Syndrome known to be associated with an increased risk of cancer eg, family history
- •of adenomatous polyposis.
- •3. Pathological condition or disease for which GH treatment is already approved in France.
- •4. Participation in any other studies involving investigational or marketed products, concomitantly or within 30 days prior to entry in the study.
- •5. Unable and/or unlikely to comprehend and/or follow GH treatment and/or the protocol.
- •6. A previous history of intolerance or hypersensitivity to the study drug, or to drugs with
- •similar chemical structures.
- •7. Patients who are known or are suspected allergic to the preservative metacresol
- •8. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with trial participation or investigational product administration or may interfere with the interpretation of trial results and in the judgment of the investigator, would make the subject inappropriate for entry into this trial. Somatropin must not be used when there is any evidence of activity of a tumour. Intracranial tumours must be inactive and antitumour therapy must be completed prior to starting growth hormone therapy. Treatment should be discontinued if there is evidence of tumour growth.
- •9. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with trial participation or investigational product administration or may interfere with the interpretation of trial results and, in the judgment of the investigator, would make the subject inappropriate for entry into this trial.
研究者
相似试验
进行中（未招募）
不适用
Growth Retardation in Children With Special Pathological Conditions or DiseaseGrowth Disorders, Growth RetardationEUCTR2004-002991-40-Outside-EU/EEAPfizer Inc46
进行中（未招募）
1 期
Short-term and longterm growth in children with asthma treated with budesonide or montelukastasthmaEUCTR2006-003013-41-DKChildren's Clinic Randers60
尚未招募
Unknown
Comparison of growth in pre & 3 months post surgery of heart disease in children under 5 years of ageCTRI/2023/07/055364Jawaharlal Nehru Medical College KLE University Belagavi
进行中（未招募）
不适用
Evaluation of growth response in short children suffering from a disease with growth retardation and treated with Somatropin: A prospective, longitudinal non-randomised, open, phase II studyEUCTR2004-005223-18-DEChildrens´ Hospital Erlangen120
已完成
3 期
Evolution Of Growth Rate In Children With Growth Retardation Due to Glucocorticosteroid Therapy And Treated By GenotonormGrowth Hormone DeficiencyNCT00163189Pfizer98